



Detection and Follow-up of Cardiovascular Disease and Risk Factors in the Southern Cone of Latin America. The CESCAS I study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000126
Article Type:	Protocol
Date Submitted by the Author:	24-Mar-2011
Complete List of Authors:	Rubinstein, Adolfo; Institute for Clinical Effectiveness and Health Policy (IECS) Irazola, Vilma; Institute for Clinical Effectiveness and Health Policy (IECS), CESCAS Poggio, Rossana; Institute for Clinical Effectiveness and Health Policy (IECS), CESCAS Bazzano, Lydia; School of Public Health and Tropical Medicine. Tulane University, Epidemiology Calandrelli, Matías; Sanatorio San Carlos, Cardiología Lanas Zanetti, Fernando; Universidad de la Frontera, CIGES Manfredi, Jose; Universidad de la República, Cardiología Olivera, Héctor; Municipalidad de Marco Paz, Secretaría de Salud Seron, Pamela; Universidad de la Frontera, CIGES Ponzo, jacqueline; Universidad de la República, Medicina Familiar He, Jiang; School of Public Health and Tropical Medicine. Tulane University, Epidemiology
Subject Heading :	Epidemiology
Keywords:	Cardiovascular Diseases, Risk Factors, Cohort Studies., Latin America

SCHOLARONE™
Manuscripts

Title

Detection and Follow-up of Cardiovascular Disease and Risk Factors in the Southern Cone of Latin America. The CESCAS I study

Abstract**Objectives**

Cardiovascular diseases (CVD) are increasing throughout the world and are the cause of almost 16.7 million deaths each year, of which 80% occur in low and middle-income countries. In Argentina, Chile and Uruguay the available data about cardiovascular risk factors come predominantly from cross-sectional studies that are principally based on self-reporting or studies conducted with small convenience samples, which do not give precise estimates. The CESCAS I study will generate reliable estimates of the prevalence, distribution, and secular trends of CVD and its risk factors in this region.

Methods and results

CESCAS I is an observational prospective cohort study. This study entails a multistage probabilistic sample of 8000 participants between the ages of 35 and 74 years old from four mid-sized cities representing the Southern cone of Latin America: two in Argentina (Bariloche and Marcos Paz), one in Chile (Temuco), and one in Uruguay (Pando-Barros Blancos). In the first phase, baseline data will be collected regarding exposure to risk factors and prevalence of CVD. Baseline data collection is conducted in two stages: 1) household and 2) health center, in order to collect information on medical history, risk factors, lifestyles, and health utilization through specific questionnaires, physical measurements, electrocardiogram and an

overnight, fasting blood sample to measure levels of serum lipids, glucose, and creatinine. In the second phase, annual follow-up data will be obtained on the incidence rate of CVD events and the association between exposure and events.

Conclusions

The lack of follow-up studies prevents our countries from implementing risk factor stratification and management strategies at a population level. The CESCAS I study data will contribute to the improvement of public health strategies based on the application of primary care interventions, thus helping to improve cardiovascular health in this region.

Article Summary

Article Focus

- Estimate the prevalence, distribution, and secular trends in major CVD events and risk factors in four cities in Argentina, Chile and Uruguay.

Key Messages

- Lack of follow-up studies prevents our countries not only from assessing local risk estimates and obtaining reliable data for burden of cardiovascular disease, but also from implementing risk factor stratification and management strategies at a population level.
- There is a strong need in the region to build the capacity and infrastructure to undertake a population based cohort study to address the knowledge gaps and to inform policy-making on the impact of CVD in the Southern Cone of Latin America

Strengths and limitations of this study'

- CESCAS I will be the first study to estimate the longitudinal trend of CVD and risk factors in Argentina, Chile and Uruguay

Introduction

Cardiovascular diseases are increasing throughout the developing world and are the cause of almost 16.7 million deaths each year, of which 80% occur in low and middle-income countries. (1) In fact, CVD deaths represent 34% of the total annual mortality rate. (2) It has been projected that in 2015, 41 million people world-wide will die of chronic diseases if effective concerted actions are not put into place for their prevention and treatment. (3) In low and middle-income countries, almost half of these deaths will occur in people younger than 70 years old, compared with only 27% amongst corresponding age groups in high-income countries.(4) Furthermore, although in recent decades age-adjusted rates for cardiovascular mortality have diminished in developed countries, rates have increased in low and middle-income countries. (1, 5)

In Latin America, it is estimated that from 1990 until 2020, death from CVD, including coronary heart disease (CHD) will increase by approximately 145% (for both men and women), compared with an increase of 28% for women and an increase of 50% for men in developed countries during the same period. (6)

Moreover, at least 75% of CVD may be explained by more proximal risk factors like unhealthy diet, low physical activity and tobacco use. (7)

In the World Health Report 2002 (WHO), 26 risk factors were evaluated and ranked by their importance. Major risk factors identified for most Latin American

1
2
3 countries were hypertension, an elevated body mass index, and alcohol and
4 tobacco use. (8) The Latin American INTERHEART study showed that the majority
5 of cardiovascular risk in the Southern Cone could be explained by tobacco use,
6 abnormal lipids, abdominal obesity and high blood pressure. (9) In Argentina,
7 recent estimates showed that more than 600,000 Disability Adjusted Life Years
8 (DALY) and almost 400,000 Years of Potential Life Lost (YPLL) were lost in 2005
9 due to CHD and stroke, where modifiable risk factors explained 75% of fatal and
10 non-fatal acute CHD and stroke events, 82% of acute CHD events and 62% of
11 strokes. Similarly, modifiable risk factors explained 76% of costs due to acute
12 events and 71% of DALY lost.(10) In Argentina, Chile and Uruguay the available
13 data about CVD risk factors come predominantly from cross-sectional studies that
14 are principally based on self-reporting or studies conducted with small convenience
15 samples, which do not give reliable estimates. (11-13). None of these studies
16 mentioned above utilized a prospective follow-up. While the ongoing ELSA study, a
17 recently established cohort in Brazil, will provide data on cardiovascular events, its
18 population is composed of employee volunteers from 6 Brazilian universities, and
19 thus it will not be able to offer population-based estimates of the impact of CVD risk
20 factors on the incidence of CVD (14)

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46 The CESCAS I study will generate reliable estimates of prevalence, distribution,
47 and secular trends in CVD and its risk factors in this region. These data will
48 contribute to the improvement of public health strategies thus helping to improve
49 cardiovascular health in Latin America.
50
51
52
53
54

55 56 57 58 59 60 **Methods**

Study Design

CESCAS I is an observational, prospective cohort study initiated in November 2010. The study is composed of two phases. In the first phase, baseline data will be collected regarding exposure to risk factors and prevalence of cardiovascular disease. In the second phase, annual follow-up data will be obtained on the incidence rate of CVD and the association between exposure and the event.

Study Population

This study entails a probabilistic sample of 8000 non-institutionalized mainly urban men and women, between the ages of 35 and 74 years old representing the general adult population in Argentina, Chile and Uruguay. Four mid-sized cities were selected: two in Argentina (Bariloche and Marcos Paz), one in Chile (Temuco), and one in Uruguay (Pando-Barros Blancos).

Sampling Method

As the prevalence of CVD risk factors is considered likely to vary by age, gender, and geographic area, the sampling method was stratified accordingly, following a complex sampling design that consisted of four stratified stages to obtain a representative sample from each of these locations (Figure 1). The first stage consisted in randomly sampling census radii from each location, stratified by socio-economic level. In the second stage a number of blocks proportional to the radius size were randomly selected. The third stage sampled households from each block using systematic sampling. If the selected house did not include a permanent residence (for example, weekend or business housing, abandoned or demolished

1
2
3 dwellings, those under construction, or addresses which were not identified) this
4
5 was replaced by another house. In the selected households all members between
6
7 35-74 yrs old were listed to create the final sampling frame. In the fourth stage one
8
9 listed member per household was randomly selected. The final sampling frame was
10
11 composed of one subject per household, stratified by gender (50% women and 50%
12
13 men) and age categories (35-44, 45-54, 55-64, and 65-74 years old) constituting a
14
15 total of 2,000 subjects per site, all of them meeting the following criteria: a
16
17 permanent resident at the location for at least 6 months per year, willing to sign a
18
19 written consent to participate, not expressing an intention to relocate within the next
20
21 two years, and able to respond autonomously to the questionnaire (without
22
23 cognitive impairment or language problems) . Replacement of selected participants
24
25 because of refusal to participate or inability to be located was not allowed. (15, 16)
26
27
28
29
30
31
32
33

34 **Recruitment Plan**

35
36 Participants are invited to participate through a letter from the site institution. The
37
38 interviewer makes the first contact with the household and arranges an appointment
39
40 for a home visit to collect questionnaire data and schedule a follow-up clinical visit.
41
42 A clinical visit is scheduled to obtain physical measurements, an electrocardiogram
43
44 (EKG) and overnight fasting blood samples. To minimize non-participation and the
45
46 potential for bias in the results, the following measures will be taken to facilitate and
47
48 encourage the participation:
49
50

- 51 •Travel assistance or home assessment for those unable to travel to the
- 52 examination centers.
- 53
- 54 •Variety of appointment times to suit all members of the community.
- 55
- 56
- 57
- 58
- 59
- 60

- Feedback of blood test and examination results to participants.

Data collection

Baseline data collection is conducted in two stages: household and health center.

In the household, an interviewer conducts a survey to collect the required information through specific questionnaires. Once the survey is complete, the interviewer proceeds to arrange the visit to the health center where the physical measurements, EKG and blood sample is obtained.

Questionnaires

A trained interviewer gathers information regarding participant characteristics including demographic, socioeconomic and health care utilization data, personal and family history of CVD and risk factors like high blood pressure, dyslipidemia, diabetes, as well as current pharmacologic and non-pharmacologic treatment. Data are also collected regarding intermittent claudication, cancer, respiratory disease, alcohol consumption and weight history using cross-culturally adapted questionnaires from the Hispanic Community Health Study / Study of Latinos (HCHS/SOL) study (17). Physical activity will be assessed through the HCHS/SOL study questionnaire adapted from the International Physical Activity questionnaire (IPAQ). (18) Information about current and former cigarette smoking, including age at which smoking was initiated, years of smoking, amount of cigarettes smoked per day, cessation attempts and treatments will be assessed using the Global Adult Tobacco Survey (GATS).(19) Use of other forms of tobacco, exposure to passive cigarette smoking and indoor pollution will also be assessed. Nutrition information will be collected using a semi-quantitative food frequency questionnaire (FFQ)

1
2
3 adapted from the National Cancer Institute Diet History Questionnaire, which has
4
5 been validated by our research team to be used in Argentina, Chile and Uruguay.
6

7
8 (20) Depression and anxiety will be assessed by the 9 item Patient Health
9
10 Questionnaire (PHQ-9) (21), which has been validated in Argentina. (22). Stressful
11
12 events and spirituality will be assessed through the HCHS/SOL study
13
14 questionnaire, cross-culturally adapted (17).

15
16
17 Locally validated versions of the SF-12 and EQ5D are used to measure health-
18
19 related quality of life and social utilities and preferences, respectively (23, 24). All
20
21 the questionnaires used in the study and their sources can be seen in Table 1.
22
23
24
25
26

27 *Blood Pressure and Anthropometric Measurements*

28
29 Trained and certified observers will measure blood pressure (BP) during the health
30
31 center visit following the recommendations of the American Heart Association (25).
32
33 According to study protocol, before BP is measured, the participant remains seated
34
35 and at rest for 5 minutes. Tea, mate or coffee consumption, as well as smoking or
36
37 exercising, in the 30 minutes prior to the testing are not permitted. A standardized
38
39 mercury or aneroid sphygmomanometer with an adequate cuff size will be used.
40
41 The cuff will be placed on the right arm of the participant, inflated to 10 mm Hg,
42
43 and then must be inflated until reaching a pressure of 30 mmHg above the level at
44
45 which the radial pulse can no longer be palpated. Three measurements are
46
47 obtained, with 30 seconds intervals between them. Korotkoff sounds are recorded,
48
49 and used to identify systolic and diastolic BP.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The weight measurement will be obtained with undergarments and without shoes.

4
5 The weight will be recorded in kilograms to one decimal place, using standing
6
7
8 scales supported on a steady surface.

9
10 The height measurement will be recorded without shoes, in centimeters to one
11
12 decimal place, on a Frankfort plane positioned at a 90-degree angle against
13
14 metallic metric tape mounted on the wall. The abdominal circumference
15
16 measurement will be recorded in centimeters to one decimal place, on a horizontal
17
18 plane at 1 cm above the belly button that generally coincides with the narrowest
19
20 circumference.
21
22
23

24 25 26 27 *Laboratory Measurements*

28
29 Overnight, fasting blood samples are drawn by venipuncture to measure levels of
30
31 serum lipids, glucose, and creatinine. The samples will be processed and
32
33 temporarily stored at the extraction site to be sent later for analysis and storage (in
34
35 ultra freezers at -80°C) in the central laboratory at the Hospital Italiano of Buenos
36
37 Aires. LDL cholesterol levels will be calculated utilizing the Friedewald equation for
38
39 the participants who have a triglyceride level <400 mg/dL. According to this
40
41 equation, total LDL cholesterol is equal to: total cholesterol – HDL cholesterol –
42
43 triglycerides/5.
44
45
46
47
48

49 50 51 *Electrocardiogram*

52
53 The study will employ a 12-lead EKG standardized at 25 mm/sec and at 1 mV of
54
55 amplitude.
56
57
58
59
60

Study outcomes

Hypertension is defined as the mean systolic BP ≥ 140 mm Hg, and/or diastolic BP ≥ 90 mm Hg, and/or self-report of current use of antihypertensive medications. (26). Obesity was defined as BMI ≥ 30 kg/m² and overweight was defined as BMI ≥ 25 kg/m². (27-30). Dyslipidemia is defined as a total cholesterol ≥ 200 mg/dL or 5.2 mmol/L, or LDL cholesterol ≥ 130 mg/dL or 3.4 mmol/L or HDL cholesterol < 40 mg/dL or 1.0 mmol/L. (31). Diabetes mellitus is defined as a fasting glucose ≥ 126 mg/dL or 7 mmol/L. Glucose intolerance is defined as a fasting glucose levels between 100 mg/dL and 125 mg/dL or 5.6 mmol/L to 6.9 mmol/L. (32) Current smoking is defined as smoking at least one cigarette per day at the time of the survey. Former-smoking is defined as a person who has been a smoker and does not smoke at the time of the survey. Passive smoking is defined as involuntarily breathing air that is contaminated by tobacco smoke. (28, 33)

During the follow-up a person is categorized as having CVD if self-reported or their self-assigned proxy reported any of the following conditions diagnosed by a physician: CVD death, acute myocardial infarction, angina, heart failure, cerebrovascular events, peripheral vascular disease or coronary or peripheral revascularization. The study Outcome Committee will review the source documents collected related to the reported event and adjudicate all CVD outcomes independently.

Training and Quality Assurance

Field work quality assurance

1
2
3 Data collection will be conducted following the standardized operations manual.
4
5 Between 5 and 10% of participants will have repeated measurements of arterial
6
7 pressure, height, weight and waist circumference to adjust for the effect of
8
9 measurement error on selected variables. All the equipment used will be certified
10
11 by international standardization norms. Periodic monitoring of data collection
12
13 procedures will be performed by the coordinating center.
14
15
16
17
18
19

20 *Laboratory quality control*

21 All laboratory measurements (total cholesterol, HDL, LDL, triglycerides, glucose
22
23 and plasma creatinine) will be performed by the central laboratory. Every
24
25 laboratory technician must complete a training program.
26
27
28
29
30
31

32 *Processing of data*

33 The database was designed using the “OpenClinica” system. (34). This is a
34
35 computerized system of related databases with web interface. The data will be
36
37 entered from each site, via the web, into electronic forms. Double data entry with
38
39 independent operators will be performed to eliminate data entry errors. The data
40
41 will be stored on a central server. Validation rules will be generated in accordance
42
43 with the nature of the variables. Automatic queries will be generated in response to
44
45 out-of-range entries to be investigated by study personnel at each site.
46
47
48
49
50
51

52 **Statistical Analysis**

53 *Sample size*

54
55
56
57
58
59
60

1
2
3 The calculated sample size is 8000 participants (2000 per site) which is consistent
4 with the recommended requirements for precision for complex surveys. This
5
6 sample will be sufficient to provide precise estimates of the prevalence of major
7
8 CVD risk factors by gender and site, in four age-defined categories: from 35 to 44,
9
10 45 to 54, 55 to 64 and 65 to 74 years old, as well as their association with the
11
12 development of CVD (35-37). The proposed sample size is sufficient to comply
13
14 with precision requirements of a complex sample that assumes that the design
15
16 effect is 1.5 and the prevalence of the risk factors of interest is 5% or greater
17
18 (Table 2).
19
20
21
22
23

24 For analysis, the capacity to detect risk factors was calculated using a statistically
25
26 significant alpha level of 0.05 and a statistical power of 85%, which will permit
27
28 detection of moderate and large relative risks.
29
30
31
32
33

34 *Statistical Analysis*

35
36 General characteristics of the population will be described. For continuous
37
38 variables, mean and median, range, standard deviation, and/or quartile range will
39
40 be calculated according to the distribution of each variable. In the case of
41
42 categorical variables, absolute and relative frequencies will be calculated.
43
44

45
46 In order to determine the prevalence and incidence of risk factors, CVD events and
47
48 the association between risk factors and CVD events, the design effect of the first
49
50 stage unit of sampling will be considered. Weighting will be based on the relation
51
52 between the number of individuals finally included in the study and the population
53
54 size and composition of each site according to the most recent census data.
55
56
57
58
59
60

1
2
3 Likewise, the analysis will be carried out by socioeconomic strata, according to
4 gender and four age categories (35–44, 45–54, 55–64, and 65–74 years old).
5
6

7 To assess association between risk factors and CVD events, linear regression and
8 simple and multiple logistic regressions will be used according to the nature of the
9 response variables. Continuous variables that are not normally distributed will be
10 evaluated by the application of transformations and categorizations wherever
11 applicable. (38)
12
13
14
15
16
17
18

19 The secular trends in risk factors over time will be evaluated with methods of
20 statistical analysis that take into account the correlation between repeated
21 measures. To evaluate the changes in risk factors over time by sub-groups of
22 interest, generalized estimation equations will be used. To estimate the rate of
23 accumulated cardiovascular incidents, the Kaplan-Meir method will be used. The
24 log rank test will be used to compare the differences between the curves of
25 accumulated incidence events. In order to quantify the relationship between risk
26 factors and the incidence of CVD events, the Cox Proportional Hazards method will
27 be used. Potential confounders and interactions will be explored. Appropriate
28 diagnostics will be carried out to test goodness of fit, collinearity, and atypical
29 observations in each model. In all cases, fulfillment of assumptions in the model
30 by means of exploration of residual behavior will be verified.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Statistical analysis software STATA 10.0 and SAS 9.0 will be used.(38-40)
49
50
51

52 **Ethical Aspects**

53 The study is carried out following the guidelines for the protection of the rights of
54 human volunteers. All investigators and personnel in the study have completed a
55
56
57
58
59
60

1
2
3 training course, certified by NIH. All participants will sign an informed consent
4
5 during the initial visit. To protect participant confidentiality the information included
6
7 in the database will not contain personal identifiers.
8
9

10 11 12 **Timeline of the study**

13
14 The baseline data collection is projected to be performed during 2011. The follow-
15
16 up phase will begin in 2012 and will consist of an annual telephone interview
17
18 continuing up to the 4th year with a second round of physical and biochemical
19
20 measures and an EKG, 2 to 3 years after the baseline measurements.
21
22
23
24
25
26

27 **Conclusions**

28
29 Despite the increasing burden of CVD in the Southern Cone, ranking first over the
30
31 last decades as a cause of mortality and morbidity, national health programs and
32
33 policies are still mostly focused on interventions aimed to tackle communicable
34
35 diseases or perinatal or childhood conditions. Therefore the actions and programs
36
37 targeted to lifestyle and nutritional changes in the population attempt to reduce
38
39 cardiovascular disease burden in high risk people (37). The lack of follow-up
40
41 studies prevents our countries not only from assessing local risk estimates and
42
43 obtaining more reliable data for burden of CVD, but also from implementing risk
44
45 factor stratification and management strategies at a population level. Accordingly,
46
47 and based on this limited and imprecise evidence, there is a strong need in the
48
49 region to build the capacity and infrastructure necessary to undertake a population-
50
51 based cohort study to address these remaining knowledge gaps and to inform
52
53 public health policy-making on the impact of CVD in our countries. The CESCAS I
54
55
56
57
58
59
60

1
2
3 study data will contribute to the improvement of public health strategies based on
4
5 the application of primary care interventions, thus helping to improve
6
7 cardiovascular health in this region.
8
9

10 11 12 **Contributory statement**

13
14
15
16
17 AR contributed to the conceptualization and design of the study and revised this
18 manuscript critically. JH contributed to the conceptualization and design of the
19 study and revised this manuscript critically. VI contributed to the conceptualization
20 and design of the study and revised this manuscript critically. RP contributed to the
21 conceptualization and design of the study and revised this manuscript critically. LB
22 contributed to the conceptualization and design of the study and revised this
23 manuscript critically. FL contributed to the conceptualization and design of the
24 study JM contributed to the conceptualization and design of the study. MC
25 contributed to the conceptualization and design of the study and acquisition of
26 data. HO contributed to the conceptualization and design of the study. PS
27 contributed to the conceptualization and design of the study. JP contributed to the
28 conceptualization and design of the study
29
30 All authors gave final approval of the version to be published.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Acknowledgements**

52
53 Eiman Jahangir and Alisson Lee, fellows of the Fogarty International Clinical
54
55 Research Fellows Program (FICRF), for the careful revision of the manuscript
56
57
58
59
60

Funding statement

NHLBI - sponsor and funder of the study. Grant number: HHSN268200900029C

References

1. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. *Eur Heart J*. 2010 Mar;31(6):642-8.
2. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. *Curr Probl Cardiol*. 2010 Feb;35(2):72-115.
3. Epping-Jordan JE, Galea G, Tukuitonga C, Beaglehole R. Preventing chronic diseases: taking stepwise action. *Lancet*. 2005 Nov 5;366(9497):1667-71.
4. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. *Lancet*. 2007 Dec 8;370(9603):1929-38.
5. Chow CK, Lock K, Teo K, Subramanian SV, McKee M, Yusuf S. Environmental and societal influences acting on cardiovascular risk factors and disease at a population level: a review. *Int J Epidemiol*. 2009 Dec;38(6):1580-94.
6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004 Sep 11-17;364(9438):937-52.
7. Murray CJL LA. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in

- 1990 and projected to 2020. . Harvard University Press 1996, World Health Organization The World Health Report: Reducing risks, Promoting Healthy Life Geneva: World Health Organization 2002)
8. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet*. 2006 May 27;367(9524):1747-57.
 9. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. *Circulation*. 2007 Mar 6;115(9):1067-74.
 10. Rubinstein A, Colantonio L, Bardach A, Caporale J, Garcia Marti S, Kopitowski K, et al. [Estimate of the cardiovascular disease burden attributable to modifiable risk factors in Argentina]. *Rev Panam Salud Publica*. Apr;27(4):237-45.
 11. ENSCH. Encuesta Nacional de Salud en Chile. http://epi.minsal.cl/epi/html/invest/ENS/ENS_mayo2004.pdf 2008.
 12. ENFR. Primera Encuesta Nacional de Factores de Riesgo. http://www.msal.gov.ar/htm/Site/enfr/resultados_completos.asp. Ministerio de Salud de la Nación Argentina. 2006.
 13. ENFRU. Primera Encuesta de Factores de Riesgo de Uruguay. <http://www.sportsalut.com.ar/eventos/cong2007/postcongreso/jueves13/6GonzaloRodriguez-PrimeraencuestaFRECNTM%5B1%5D%5B1%5D.S.pdf> 2006.
 14. ELSA. ELSA Brasil: the greatest epidemiological study in Latin America. *Rev Saude Publica*. 2009 Feb;43(1).

15. Silva Ayçaguer L. Diseño Razonado De Muestras Y Captación De Datos Para La Investigación Sanitaria. Editorial Díaz de Santos, First edition. . 2000.
16. Levy P. Lemeshow, S. Sampling of Populations: Methods and Applications. Wiley Series in Survey Methodology, 3rd Edition. 1999.
17. SOL/HCHS. SOL study of latinos. <http://www.csc.unc.edu/hchs>.
18. IPAQ. International Physical Activity Questionnaire. <http://www.ipaq.ki.se/downloads.htm>.
19. GATS. Global Adult Tobacco Survey. <http://www.tobaccofreecenter.org>.
20. Elorriaga N. Personal communication. Unpublished results.
21. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001 Sep;16(9):606-13.
22. Bonicatto S. Screening of mental disorders in primary care: linguistic adaptation procedure of a diagnostic instrument. *Acta psiquiátr psicol Am Lat*;45(3):223-34, sept 1999. 1999.
23. Augustovski FA, Irazola VE, Velazquez AP, Gibbons L, Craig BM. Argentine valuation of the EQ-5D health states. *Value Health*. 2009 Jun;12(4):587-96.
24. Augustovski FA, Lewin G, Elorrio EG, Rubinstein A. The Argentine-Spanish SF-36 Health Survey was successfully validated for local outcome research. *J Clin Epidemiol*. 2008 Dec;61(12):1279-84.
25. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, et al. Human blood pressure determination by sphygmomanometry. *Circulation*. 1993 Nov;88(5 Pt 1):2460-70.
26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The Seventh Report of the Joint National Committee on Prevention,

- 1
2
3 Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
4
5 JAMA. 2003 May 21;289(19):2560-72.
6
7
8 27. Schargrotsky H, Hernandez-Hernandez R, Champagne BM, Silva H,
9
10 Vinueza R, Silva Aycaguer LC, et al. CARMELA: assessment of cardiovascular risk
11
12 in seven Latin American cities. Am J Med. 2008 Jan;121(1):58-65.
13
14
15 28. MESA. Multi-Ethnic Study of Atherosclerosis. <http://www.mesa-nhlbi.org/>.
16
17
18 29. CARDIA. Coronary Aartery Risk Development in Young Adults.
19
20 <http://www.cardia.dopm.uab.edu/>
21
22
23 30. NHANES. National Health and Nutrition Examination Survey.
24
25 <http://www.cdc.gov/nchs/nhanes.htm>.
26
27
28 31. Third Report of the National Cholesterol Education Program (NCEP) Expert
29
30 Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
31
32 (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421.
33
34
35 32. Report of the expert committee on the diagnosis and classification of
36
37 diabetes mellitus. Diabetes Care. 2003 Jan;26 Suppl 1:S5-20.
38
39
40 33. Gu D, Wu X, Reynolds K, Duan X, Xin X, Reynolds RF, et al. Cigarette
41
42 smoking and exposure to environmental tobacco smoke in China: the international
43
44 collaborative study of cardiovascular disease in Asia. Am J Public Health. 2004
45
46 Nov;94(11):1972-6.
47
48
49 34. Openclinica. <https://community.openclinica.com/>.
50
51
52 35. Whelton PK. Epidemiology of hypertension. Lancet. 1994 Jul
53
54 9;344(8915):101-6.
55
56
57 36. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood
58
59 pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in
60

1
2
3 blood pressure: prospective observational studies corrected for the regression
4 dilution bias. Lancet. 1990 Mar 31;335(8692):765-74.
5
6

7
8 37. Rubinstein A, Colantonio L, Bardach A, Caporale J, Marti SG, Kopitowski K,
9 et al. Estimation of the burden of cardiovascular disease attributable to modifiable
10 risk factors and cost-effectiveness analysis of preventative interventions to reduce
11 this burden in Argentina. BMC Public Health.10:627.
12
13

14
15 38. Hosmer D. Lemeshow, S. Applied logistic regression. Wiley Series in
16 probability and statistics by 2nd Edition. . 2000.
17
18

19
20 39. Kleinbaum D. Kupper, L. Nizam, A. Muller, K. Applied Regression Analysis
21 and Multivariable Methods (Duxbury Applied) 3rd Edition. . 2007.
22
23

24
25 40. Hosmer D. May, S. Applied Survival Analysis: Regression Modeling of Time
26 to Event Data (Wiley Series in Probability and Statistics), 2nd Edition. . 2008.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLE 1. Data collection items in the CESCAS I study

Type of data	Components	Instrument
General information	Socio-demographic and economic data, type and health services utilization	SOL/HCHS*
Claudication	Location, Functional class	SOL/HCHS*
History	Cardiovascular, respiratory, hypertension, dyslipidemia, diabetes, pharmacologic and non-pharmacologic treatment and cancer	SOL/HCHS*
Alcohol	Level of consumption (daily quantity, frequency, type of alcoholic beverage)	SOL/HCHS*
Physical Activity	Type of activity, frequency and intensity, in free time and work	IPAQ
Spirituality	Importance, religious practice	SOL/HCHS*
Nutrition	Types of foods, quantity and frequency	FFQ
Smoking	Current, former and passive smoker. Other types of tobacco use (pipe, cigar)	GATS
Mental health	Depression, traumatic events, anxiety	PHQ-9/ SOL/HCHS*
Global health		SF-12
Quality of life		EQ5D
Physical examination	Blood pressure, weight, height and waist circumference	
Laboratory	Total cholesterol, HDL cholesterol, triglycerides, glucose and creatinine	
Electrocardiogram	25 mm/sec and at 1 mV of amplitude	

*Forms from Hispanic Community Health Study / Study of Latinos, cross-culturally adapted for use in Argentina, Chile and Uruguay

TABLE 2. Sample size for a highly complex study design for effect and design of specific proportion

Proportion	Design Effect				
	1.0	1.5	2.0	2.5	3.0
0.26-0.50	30	45	60	75	90
0.25	32	48	64	80	96
0.20	40	60	80	100	120
0.15	53	80	107	133	160
0.10	80	120	160	200	240
0.05	160	240	320	400	480

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


This cohort study will comply with the STROBE statement for this type of observational studies

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE 1. Sampling procedure in CESCAS I study



169x135mm (96 x 96 DPI)



Detection and Follow-up of Cardiovascular Disease and Risk Factors in the Southern Cone of Latin America. The CESCAS I study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000126.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Apr-2011
Complete List of Authors:	Rubinstein, Adolfo; Institute for Clinical Effectiveness and Health Policy (IECS) Irazola, Vilma; Institute for Clinical Effectiveness and Health Policy (IECS), CESCAS Poggio, Rossana; Institute for Clinical Effectiveness and Health Policy (IECS), CESCAS Bazzano, Lydia; School of Public Health and Tropical Medicine. Tulane University, Epidemiology Calandrelli, Matías; Sanatorio San Carlos, Cardiología Lanas Zanetti, Fernando; Universidad de la Frontera, CIGES Manfredi, Jose; Universidad de la República, Cardiología Olivera, Héctor; Municipalidad de Marco Paz, Secretaría de Salud Seron, Pamela; Universidad de la Frontera, CIGES Ponzo, jacqueline; Universidad de la República, Medicina Familiar He, Jiang; School of Public Health and Tropical Medicine. Tulane University, Epidemiology
Subject Heading :	Epidemiology
Keywords:	Cardiovascular Diseases, Risk Factors, Cohort Studies., Latin America

SCHOLARONE™
Manuscripts

Title

Detection and Follow-up of Cardiovascular Disease and Risk Factors in the Southern Cone of Latin America. The CESCAS I study

Abstract

Introduction

Cardiovascular diseases (CVD) are increasing throughout the world and cause 16.7 million deaths each year, of which 80% occur in low-middle income countries. In Argentina, Chile and Uruguay the available data about cardiovascular risk factors come predominantly from cross-sectional studies that are principally based on self-reporting or studies conducted with small convenience samples. The CESCAS I study will generate reliable estimates of the prevalence, distribution, and secular trends of CVD and its risk factors in this region.

Methods and analysis

CESCAS I is an observational prospective cohort study. This study entails a multistage probabilistic sample of 8000 participants between the ages of 35 and 74 years old from four mid-sized cities representing the Southern cone of Latin America: two in Argentina (Bariloche and Marcos Paz), one in Chile (Temuco), and one in Uruguay (Pando-Barros Blancos). In the first phase, baseline data will be collected regarding exposure to risk factors and prevalence of CVD. Baseline data collection is conducted in two stages: 1) household and 2) health center, in order to collect information on medical history, risk factors, lifestyles, and health utilization through specific questionnaires, physical measurements, electrocardiogram and an overnight, fasting blood sample to measure levels of serum lipids, glucose, and

1
2
3 creatinine. In the second phase, annual follow-up data will be obtained on the
4
5 incidence rate of CVD events and the association between exposure and events.
6
7

8 **Ethics and Dissemination**

9
10 The protocol has obtained formal ethical approval from the IRB's in Argentina,
11
12 Chile, Uruguay, and USA.

13
14 The lack of follow-up studies prevents our countries from implementing risk factor
15
16 stratification and management strategies at a population level. The CESCAS I
17
18 study data will contribute to the improvement of public health strategies based on
19
20 the application of primary care interventions, thus helping to improve
21
22 cardiovascular health in this region.
23
24
25
26
27
28

29 **Article Summary**

30 **Article Focus**

- 31
32
33
34
 - Estimate the prevalence, distribution, and secular trends in major CVD
35
36 events and risk factors in four cities in Argentina, Chile and Uruguay.
37
38

39 **Key Messages**

- 40
41
 - Lack of follow-up studies prevents our countries not only from assessing
42
43 local risk estimates and obtaining reliable data for burden of cardiovascular
44
45 disease, but also from implementing risk factor stratification and
46
47 management strategies at a population level.
48
49
50
 - There is a strong need in the region to build the capacity and infrastructure
51
52 to undertake a population based cohort study to address the knowledge
53
54
55
56
57
58
59
60

gaps and to inform policy-making on the impact of CVD in the Southern Cone of Latin America

Strengths and limitations of this study'

- CESCAS I will be the first study to estimate the longitudinal trend of CVD and risk factors in Argentina, Chile and Uruguay

Introduction

Cardiovascular diseases are increasing throughout the developing world and are the cause of almost 16.7 million deaths each year, of which 80% occur in low and middle-income countries. (1) In fact, CVD deaths represent 34% of the total annual mortality rate. (2) It has been projected that in 2015, 41 million people world-wide will die of chronic diseases if effective concerted actions are not put into place for their prevention and treatment. (3) In low and middle-income countries, almost half of these deaths will occur in people younger than 70 years old, compared with only 27% amongst corresponding age groups in high-income countries.(4) Furthermore, although in recent decades age-adjusted rates for cardiovascular mortality have diminished in developed countries, rates have increased in low and middle-income countries. (1, 5)

In Latin America, it is estimated that from 1990 until 2020, death from CVD, including coronary heart disease (CHD) will increase by approximately 145% (for both men and women), compared with an increase of 28% for women and an increase of 50% for men in developed countries during the same period. (6)

Moreover, at least 75% of CVD may be explained by more proximal risk factors like unhealthy diet, low physical activity and tobacco use. (7)

1
2
3 In the World Health Report 2002 (WHO), 26 risk factors were evaluated and
4 ranked by their importance. Major risk factors identified for most Latin American
5 countries were hypertension, an elevated body mass index, and alcohol and
6 tobacco use. (8) The Latin American INTERHEART study showed that the majority
7 of cardiovascular risk in the Southern Cone could be explained by tobacco use,
8 abnormal lipids, abdominal obesity and high blood pressure. (9) In Argentina,
9 recent estimates showed that more than 600,000 Disability Adjusted Life Years
10 (DALY) and almost 400,000 Years of Potential Life Lost (YPLL) were lost in 2005
11 due to CHD and stroke, where modifiable risk factors explained 75% of fatal and
12 non-fatal acute CHD and stroke events, 82% of acute CHD events and 62% of
13 strokes. Similarly, modifiable risk factors explained 76% of costs due to acute
14 events and 71% of DALY lost. (10) In Argentina, Chile and Uruguay the available
15 data about CVD risk factors come predominantly from cross-sectional studies that
16 are principally based on self-reporting or studies conducted with small convenience
17 samples, which do not give reliable estimates. (11-13). None of these studies
18 mentioned above utilized a prospective follow-up. While the ongoing ELSA study, a
19 recently established cohort in Brazil, will provide data on cardiovascular events, its
20 population is composed of employee volunteers from 6 Brazilian universities, and
21 thus it will not be able to offer population-based estimates of the impact of CVD risk
22 factors on the incidence of CVD (14)

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The CESCAS I study will generate reliable estimates of prevalence, distribution,
and secular trends in CVD and its risk factors in this region. These data will
contribute to the improvement of public health strategies thus helping to improve
cardiovascular health in Latin America.

Methods

Study Design

CESCAS I is an observational, prospective cohort study initiated in November 2010. The study is composed of two phases. In the first phase, baseline data will be collected regarding exposure to risk factors and prevalence of cardiovascular disease. In the second phase, annual follow-up data will be obtained on the incidence rate of CVD and the association between exposure and the event.

Study Population

This study entails a probabilistic sample of 8000 non-institutionalized mainly urban men and women, between the ages of 35 and 74 years old representing the general adult population in Argentina, Chile and Uruguay. Four mid-sized cities were selected: two in Argentina (Bariloche and Marcos Paz), one in Chile (Temuco), and one in Uruguay (Pando-Barros Blancos).

Sampling Method

As the prevalence of CVD risk factors is considered likely to vary by age, gender, and geographic area, the sampling method was stratified accordingly, following a complex sampling design that consisted of four stratified stages to obtain a representative sample from each of these locations (Figure 1). The first stage consisted in randomly sampling census radii from each location, stratified by socio-economic level. In the second stage a number of blocks proportional to the radius size were randomly selected. The third stage sampled households from each block

1
2
3 using systematic sampling. If the selected house did not include a permanent
4 residence (for example, weekend or business housing, abandoned or demolished
5 dwellings, those under construction, or addresses which were not identified) this
6 was replaced by another house. In the selected households all members between
7 35-74 yrs old were listed to create the final sampling frame. In the fourth stage one
8 listed member per household was randomly selected. The final sampling frame was
9 composed of one subject per household, stratified by gender (50% women and 50%
10 men) and age categories (35-44, 45-54, 55-64, and 65-74 years old) constituting a
11 total of 2,000 subjects per site, all of them meeting the following criteria: a
12 permanent resident at the location for at least 6 months per year, willing to sign a
13 written consent to participate, not expressing an intention to relocate within the next
14 two years, and able to respond autonomously to the questionnaire (without
15 cognitive impairment or language problems) . Replacement of selected participants
16 because of refusal to participate or inability to be located was not allowed. (15, 16)
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Recruitment Plan**

40 Participants are invited to participate through a letter from the site institution. The
41 interviewer makes the first contact with the household and arranges an appointment
42 for a home visit to collect questionnaire data and schedule a follow-up clinical visit.
43 A clinical visit is scheduled to obtain physical measurements, an electrocardiogram
44 (EKG) and overnight fasting blood samples. To minimize non-participation and the
45 potential for bias in the results, the following measures will be taken to facilitate and
46 encourage the participation:
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Travel assistance or home assessment for those unable to travel to the examination centers.
- Variety of appointment times to suit all members of the community.
- Feedback of blood test and examination results to participants.

Data collection

Baseline data collection is conducted in two stages: household and health center. In the household, an interviewer conducts a survey to collect the required information through specific questionnaires. Once the survey is complete, the interviewer proceeds to arrange the visit to the health center where the physical measurements, EKG and blood sample is obtained.

Questionnaires

A trained interviewer gathers information regarding participant characteristics including demographic, socioeconomic and health care utilization data, personal and family history of CVD and risk factors like high blood pressure, dyslipidemia, diabetes, as well as current pharmacologic and non-pharmacologic treatment. Data are also collected regarding intermittent claudication, cancer, respiratory disease, alcohol consumption and weight history using cross-culturally adapted questionnaires from the Hispanic Community Health Study / Study of Latinos (HCHS/SOL) study (17). Physical activity will be assessed through the HCHS/SOL study questionnaire adapted from the International Physical Activity questionnaire (IPAQ). (18) Information about current and former cigarette smoking, including age at which smoking was initiated, years of smoking, amount of cigarettes smoked per day, cessation attempts and treatments will be assessed using the Global Adult

1
2
3 Tobacco Survey (GATS).(19) Use of other forms of tobacco, exposure to passive
4 cigarette smoking and indoor pollution will also be assessed. Nutrition information
5 will be collected using a semi-quantitative food frequency questionnaire (FFQ)
6 adapted from the National Cancer Institute Diet History Questionnaire, which has
7 been validated by our research team to be used in Argentina, Chile and Uruguay.
8 (20) Depression and anxiety will be assessed by the 9 item Patient Health
9 Questionnaire (PHQ-9) (21), which has been validated in Argentina. (22). Stressful
10 events and spirituality will be assessed through the HCHS/SOL study
11 questionnaire, cross-culturally adapted (17).
12
13 Locally validated versions of the SF-12 and EQ5D are used to measure health-
14 related quality of life and social utilities and preferences, respectively (23, 24). All
15 the questionnaires used in the study and their sources can be seen in Table 1.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 *Blood Pressure and Anthropometric Measurements*

35
36 Trained and certified observers will measure blood pressure (BP) during the health
37 center visit following the recommendations of the American Heart Association (25).
38 According to study protocol, before BP is measured, the participant remains seated
39 and at rest for 5 minutes. Tea, mate or coffee consumption, as well as smoking or
40 exercising, in the 30 minutes prior to the testing are not permitted. A standardized
41 mercury or aneroid sphygmomanometer with an adequate cuff size will be used.
42
43 The cuff will be placed on the right arm of the participant, inflated to 10 mm Hg,
44 and then must be inflated until reaching a pressure of 30 mmHg above the level at
45 which the radial pulse can no longer be palpated. Three measurements are
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 obtained, with 30 seconds intervals between them. Korotkoff sounds are recorded,
4
5 and used to identify systolic and diastolic BP.
6
7

8 The weight measurement will be obtained with undergarments and without shoes.
9

10 The weight will be recorded in kilograms to one decimal place, using standing
11
12 scales supported on a steady surface.
13

14 The height measurement will be recorded without shoes, in centimeters to one
15
16 decimal place, on a Frankfort plane positioned at a 90-degree angle against
17
18 metallic metric tape mounted on the wall. The abdominal circumference
19
20 measurement will be recorded in centimeters to one decimal place, on a horizontal
21
22 plane at 1 cm above the belly button that generally coincides with the narrowest
23
24 circumference.
25
26
27
28
29
30
31

32 *Laboratory Measurements*

33
34 Overnight, fasting blood samples are drawn by venipuncture to measure levels of
35
36 serum lipids, glucose, and creatinine. The samples will be processed and
37
38 temporarily stored at the extraction site to be sent later for analysis and storage (in
39
40 ultra freezers at -80°C) in the central laboratory at the Hospital Italiano of Buenos
41
42 Aires. LDL cholesterol levels will be calculated utilizing the Friedewald equation for
43
44 the participants who have a triglyceride level <400 mg/dL. According to this
45
46 equation, total LDL cholesterol is equal to: total cholesterol – HDL cholesterol –
47
48 triglycerides/5.
49
50
51
52
53
54

55 *Electrocardiogram*

56
57
58
59
60

1
2
3 The study will employ a 12-lead EKG standardized at 25 mm/sec and at 1 mV of
4
5 amplitude.
6
7

8 9 10 **Study outcomes**

11
12 Hypertension is defined as the mean systolic BP ≥ 140 mm Hg, and/or
13 diastolic BP ≥ 90 mm Hg, and/or self-report of current use of antihypertensive
14 medications. (26). Obesity was defined as BMI ≥ 30 kg/m² and overweight was
15 defined as BMI ≥ 25 kg/m². (27-30). Dyslipidemia is defined as a total cholesterol \geq
16 200 mg/dL or 5.2 mmol/L, or LDL cholesterol ≥ 130 mg/dL or 3.4 mmol/L or HDL
17 cholesterol < 40 mg/dL or 1.0 mmol/L. (31). Diabetes mellitus is defined as a fasting
18 glucose ≥ 126 mg/dL or 7.0 mmol/L. Glucose intolerance is defined as a fasting
19 glucose levels between 100 mg/dL and 125 mg/dL or 5.6 mmol/L to 6.9
20 mmol/L. (32) Current smoking is defined as smoking at least one cigarette per day
21 at the time of the survey. Former-smoking is defined as a person who has been a
22 smoker and does not smoke at the time of the survey. Passive smoking is defined
23 as involuntarily breathing air that is contaminated by tobacco smoke. (28, 33)
24
25 During the follow-up a person is categorized as having CVD if self-reported or their
26 self-assigned proxy reported any of the following conditions diagnosed by a
27 physician: CVD death, acute myocardial infarction, angina, heart failure, cerebro-
28 vascular events, peripheral vascular disease or coronary or peripheral
29 revascularization. The study Outcome Committee will review the source
30 documents collected related to the reported event and adjudicate all CVD
31 outcomes independently.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Training and Quality Assurance

Field work quality assurance

Data collection will be conducted following the standardized operations manual. Between 5 and 10% of participants will have repeated measurements of arterial pressure, height, weight and waist circumference to adjust for the effect of measurement error on selected variables. All the equipment used will be certified by international standardization norms. Periodic monitoring of data collection procedures will be performed by the coordinating center.

Laboratory quality control

All laboratory measurements (total cholesterol, HDL, LDL, triglycerides, glucose and plasma creatinine) will be performed by the central laboratory. Every laboratory technician must complete a training program.

Processing of data

The database was designed using the “OpenClinica” system. (34). This is a computerized system of related databases with web interface. The data will be entered from each site, via the web, into electronic forms. Double data entry with independent operators will be performed to eliminate data entry errors. The data will be stored on a central server. Validation rules will be generated in accordance with the nature of the variables. Automatic queries will be generated in response to out-of-range entries to be investigated by study personnel at each site.

Statistical Analysis

Sample size

The calculated sample size is 8000 participants (2000 per site) which is consistent with the recommended requirements for precision for complex surveys. This sample will be sufficient to provide precise estimates of the prevalence of major CVD risk factors by gender and site, in four age-defined categories: from 35 to 44, 45 to 54, 55 to 64 and 65 to 74 years old, as well as their association with the development of CVD (35-37). The proposed sample size is sufficient to comply with precision requirements of a complex sample that assumes that the design effect is 1.5 and the prevalence of the risk factors of interest is 5% or greater (Table 2).

For analysis, the capacity to detect risk factors was calculated using a statistically significant alpha level of 0.05 and a statistical power of 85%, which will permit detection of moderate and large relative risks.

Statistical Analysis

General characteristics of the population will be described. For continuous variables, mean and median, range, standard deviation, and/or quartile range will be calculated according to the distribution of each variable. In the case of categorical variables, absolute and relative frequencies will be calculated.

In order to determine the prevalence and incidence of risk factors, CVD events and the association between risk factors and CVD events, the design effect of the first stage unit of sampling will be considered. Weighting will be based on the relation between the number of individuals finally included in the study and the population size and composition of each site according to the most recent census data.

1
2
3 Likewise, the analysis will be carried out by socioeconomic strata, according to
4 gender and four age categories (35–44, 45–54, 55–64, and 65–74 years old).
5
6

7 To assess association between risk factors and CVD events, linear regression and
8 simple and multiple logistic regressions will be used according to the nature of the
9 response variables. Continuous variables that are not normally distributed will be
10 evaluated by the application of transformations and categorizations wherever
11 applicable. (38)
12
13
14
15
16
17
18

19 The secular trends in risk factors over time will be evaluated with methods of
20 statistical analysis that take into account the correlation between repeated
21 measures. To evaluate the changes in risk factors over time by sub-groups of
22 interest, generalized estimation equations will be used. To estimate the rate of
23 accumulated cardiovascular incidents, the Kaplan-Meier method will be used. The
24 log rank test will be used to compare the differences between the curves of
25 accumulated incidence events. In order to quantify the relationship between risk
26 factors and the incidence of CVD events, the Cox Proportional Hazards method will
27 be used. Potential confounders and interactions will be explored. Appropriate
28 diagnostics will be carried out to test goodness of fit, collinearity, and atypical
29 observations in each model. In all cases, fulfillment of assumptions in the model
30 by means of exploration of residual behavior will be verified.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Statistical analysis software STATA 10.0 and SAS 9.0 will be used.(38-40)
49
50
51

52 **Ethical Aspects**

53
54
55 The study is carried out following the guidelines for the protection of the rights of
56 human volunteers. All investigators and personnel in the study have completed a
57
58
59
60

1
2
3 training course, certified by NIH. All participants will sign an informed consent
4
5 during the initial visit. To protect participant confidentiality the information included
6
7 in the database will not contain personal identifiers.
8
9

10 11 12 **Timeline of the study**

13
14 The baseline data collection is projected to be performed during 2011. The follow-
15
16 up phase will begin in 2012 and will consist of an annual telephone interview
17
18 continuing up to the 4th year with a second round of physical and biochemical
19
20 measures and an EKG, 2 to 3 years after the baseline measurements.
21
22
23
24

25 26 27 **Conclusions**

28
29 Despite the increasing burden of CVD in the Southern Cone, ranking first over the
30
31 last decades as a cause of mortality and morbidity, national health programs and
32
33 policies are still mostly focused on interventions aimed to tackle communicable
34
35 diseases or perinatal or childhood conditions. Therefore the actions and programs
36
37 targeted to lifestyle and nutritional changes in the population attempt to reduce
38
39 cardiovascular disease burden in high risk people (37). The lack of follow-up
40
41 studies prevents our countries not only from assessing local risk estimates and
42
43 obtaining more reliable data for burden of CVD, but also from implementing risk
44
45 factor stratification and management strategies at a population level. Accordingly,
46
47 and based on this limited and imprecise evidence, there is a strong need in the
48
49 region to build the capacity and infrastructure necessary to undertake a population-
50
51 based cohort study to address these remaining knowledge gaps and to inform
52
53 public health policy-making on the impact of CVD in our countries. The CESCAS I
54
55
56
57
58
59
60

1
2
3 study data will contribute to the improvement of public health strategies based on
4
5 the application of primary care interventions, thus helping to improve
6
7 cardiovascular health in this region.
8
9

10 11 12 **Contributory statement**

13
14
15
16
17 AR contributed to the conceptualization and design of the study and revised this
18 manuscript critically. JH contributed to the conceptualization and design of the
19 study and revised this manuscript critically. VI contributed to the conceptualization
20 and design of the study and revised this manuscript critically. RP contributed to the
21 conceptualization and design of the study and revised this manuscript critically. LB
22 contributed to the conceptualization and design of the study and revised this
23 manuscript critically. FL contributed to the conceptualization and design of the
24 study and revised this manuscript critically. JM contributed to the conceptualization
25 and design of the study and revised this manuscript critically. MC contributed to the
26 conceptualization and design of the study and revised this manuscript critically. HO
27 contributed to the conceptualization and design of the study and revised this
28 manuscript critically. PS contributed to the conceptualization and design of the
29 study and revised this manuscript critically. JP contributed to the conceptualization
30 and design of the study and revised this manuscript critically.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 All authors gave final approval of the version to be published.
51
52
53
54

55 **Acknowledgements**

56
57
58
59
60

1
2
3 Eiman Jahangir and Alisson Lee, fellows of the Fogarty International Clinical
4 Research Fellows Program (FICRF), for the careful revision of the manuscript
5
6
7
8
9

10 **References**

- 11
12 1. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. Novel therapeutic concepts: the
13 epidemic of cardiovascular disease in the developing world: global implications.
14 Eur Heart J. 2010 Mar;31(6):642-8.
15
16
- 17 2. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing
18 epidemic of coronary heart disease in low- and middle-income countries. Curr
19 Probl Cardiol. 2010 Feb;35(2):72-115.
20
21
- 22 3. Epping-Jordan JE, Galea G, Tukuitonga C, Beaglehole R. Preventing
23 chronic diseases: taking stepwise action. Lancet. 2005 Nov 5;366(9497):1667-71.
24
25
- 26 4. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and
27 costs of chronic diseases in low-income and middle-income countries. Lancet.
28 2007 Dec 8;370(9603):1929-38.
29
30
- 31 5. Chow CK, Lock K, Teo K, Subramanian SV, McKee M, Yusuf S.
32 Environmental and societal influences acting on cardiovascular risk factors and
33 disease at a population level: a review. Int J Epidemiol. 2009 Dec;38(6):1580-94.
34
35
- 36 6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of
37 potentially modifiable risk factors associated with myocardial infarction in 52
38 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-
39 17;364(9438):937-52.
40
41
- 42 7. Murray CJL LA. The Global Burden of Disease: a comprehensive
43 assessment of mortality and disability from diseases, injuries, and risk factors in
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1990 and projected to 2020. . Harvard University Press 1996, World Health
4
5
6 Organization The World Health Report:
7
8 Reducing risks, Promoting Healthy Life Geneva: World Health Organization 2002)
9
10 8. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and
11
12 regional burden of disease and risk factors, 2001: systematic analysis of population
13
14 health data. *Lancet*. 2006 May 27;367(9524):1747-57.
15
16
17 9. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, et al. Risk
18
19 factors for acute myocardial infarction in Latin America: the INTERHEART Latin
20
21 American study. *Circulation*. 2007 Mar 6;115(9):1067-74.
22
23
24 10. Rubinstein A, Colantonio L, Bardach A, Caporale J, Garcia Marti S,
25
26 Kopitowski K, et al. [Estimate of the cardiovascular disease burden attributable to
27
28 modifiable risk factors in Argentina]. *Rev Panam Salud Publica*. Apr;27(4):237-45.
29
30
31 11. ENSCH. Encuesta Nacional de Salud en Chile.
32
33 http://epi.minsal.cl/epi/html/invest/ENS/ENS_mayo2004.pdf 2008.
34
35
36 12. ENFR. Primera Encuesta Nacional de Factores de Riesgo.
37
38 http://www.msal.gov.ar/htm/Site/enfr/resultados_completos.asp. Ministerio de
39
40 Salud de la Nación Argentina. 2006.
41
42
43 13. ENFRU. Primera Encuesta de Factores de Riesgo de Uruguay.
44
45 <http://www.sportsalut.com.ar/eventos/cong2007/postcongreso/jueves13/6Gonzalo>
46
47 Rodriguez-PrimeraencuestaFRECNTM%5B1%5D%5B1%5D.S.pdf
48
49 2006.
50
51
52 14. ELSA. ELSA Brasil: the greatest epidemiological study in Latin America.
53
54 *Rev Saude Publica*. 2009 Feb;43(1).
55
56
57
58
59
60

15. Silva Ayçaguer L. Diseño Razonado De Muestras Y Captación De Datos Para La Investigación Sanitaria. Editorial Díaz de Santos, First edition. . 2000.
16. Levy P. Lemeshow, S. Sampling of Populations: Methods and Applications. Wiley Series in Survey Methodology, 3rd Edition. 1999.
17. SOL/HCHS. SOL study of latinos. <http://www.csc.unc.edu/hchs>.
18. IPAQ. International Physical Activity Questionnaire. <http://www.ipaq.ki.se/downloads.htm>.
19. GATS. Global Adult Tobacco Survey. <http://www.tobaccofreecenter.org>.
20. Elorriaga N. Personal communication. Unpublished results.
21. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001 Sep;16(9):606-13.
22. Bonicatto S. Screening of mental disorders in primary care: linguistic adaptation procedure of a diagnostic instrument. *Acta psiquiátr psicol Am Lat*;45(3):223-34, sept 1999. 1999.
23. Augustovski FA, Irazola VE, Velazquez AP, Gibbons L, Craig BM. Argentine valuation of the EQ-5D health states. *Value Health*. 2009 Jun;12(4):587-96.
24. Augustovski FA, Lewin G, Elorrio EG, Rubinstein A. The Argentine-Spanish SF-36 Health Survey was successfully validated for local outcome research. *J Clin Epidemiol*. 2008 Dec;61(12):1279-84.
25. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, et al. Human blood pressure determination by sphygmomanometry. *Circulation*. 1993 Nov;88(5 Pt 1):2460-70.
26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The Seventh Report of the Joint National Committee on Prevention,

- 1
2
3 Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
4
5 JAMA. 2003 May 21;289(19):2560-72.
6
7
8 27. Schargrodsky H, Hernandez-Hernandez R, Champagne BM, Silva H,
9
10 Vinueza R, Silva Aycaguer LC, et al. CARMELA: assessment of cardiovascular risk
11
12 in seven Latin American cities. Am J Med. 2008 Jan;121(1):58-65.
13
14
15 28. MESA. Multi-Ethnic Study of Atherosclerosis. <http://www.mesa-nhlbi.org/>.
16
17
18 29. CARDIA. Coronary Aartery Risk Development in Young Adults.
19
20 <http://www.cardia.dopm.uab.edu/>
21
22
23 30. NHANES. National Health and Nutrition Examination Survey.
24
25 <http://www.cdc.gov/nchs/nhanes.htm>.
26
27
28 31. Third Report of the National Cholesterol Education Program (NCEP) Expert
29
30 Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
31
32 (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421.
33
34
35 32. Report of the expert committee on the diagnosis and classification of
36
37 diabetes mellitus. Diabetes Care. 2003 Jan;26 Suppl 1:S5-20.
38
39
40 33. Gu D, Wu X, Reynolds K, Duan X, Xin X, Reynolds RF, et al. Cigarette
41
42 smoking and exposure to environmental tobacco smoke in China: the international
43
44 collaborative study of cardiovascular disease in Asia. Am J Public Health. 2004
45
46 Nov;94(11):1972-6.
47
48
49 34. Openclinica. <https://community.openclinica.com/>.
50
51
52 35. Whelton PK. Epidemiology of hypertension. Lancet. 1994 Jul
53
54 9;344(8915):101-6.
55
56
57 36. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood
58
59 pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in
60

1
2
3 blood pressure: prospective observational studies corrected for the regression
4 dilution bias. Lancet. 1990 Mar 31;335(8692):765-74.
5
6

7
8 37. Rubinstein A, Colantonio L, Bardach A, Caporale J, Marti SG, Kopitowski K,
9 et al. Estimation of the burden of cardiovascular disease attributable to modifiable
10 risk factors and cost-effectiveness analysis of preventative interventions to reduce
11 this burden in Argentina. BMC Public Health.10:627.
12
13

14
15 38. Hosmer D. Lemeshow, S. Applied logistic regression. Wiley Series in
16 probability and statistics by 2nd Edition. . 2000.
17
18

19
20 39. Kleinbaum D. Kupper, L. Nizam, A. Muller, K. Applied Regression Analysis
21 and Multivariable Methods (Duxbury Applied) 3rd Edition. . 2007.
22
23

24
25 40. Hosmer D. May, S. Applied Survival Analysis: Regression Modeling of Time
26 to Event Data (Wiley Series in Probability and Statistics), 2nd Edition. . 2008.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLE 1. Data collection items in the CESCAS I study

Type of data	Components	Instrument
General information	Socio-demographic and economic data, type and health services utilization	SOL/HCHS*
Claudication	Location, Functional class	SOL/HCHS*
History	Cardiovascular, respiratory, hypertension, dyslipidemia, diabetes, pharmacologic and non-pharmacologic treatment and cancer	SOL/HCHS*
Alcohol	Level of consumption (daily quantity, frequency, type of alcoholic beverage)	SOL/HCHS*
Physical Activity	Type of activity, frequency and intensity, in free time and work	IPAQ
Spirituality	Importance, religious practice	SOL/HCHS*
Nutrition	Types of foods, quantity and frequency	FFQ
Smoking	Current, former and passive smoker. Other types of tobacco use (pipe, cigar)	GATS
Mental health	Depression, traumatic events, anxiety	PHQ-9/ SOL/HCHS*
Global health		SF-12
Quality of life		EQ5D
Physical examination	Blood pressure, weight, height and waist circumference	
Laboratory	Total cholesterol, HDL cholesterol, triglycerides, glucose and creatinine	
Electrocardiogram	25 mm/sec and at 1 mV of amplitude	

*Forms from Hispanic Community Health Study / Study of Latinos, cross-culturally adapted for use in Argentina, Chile and Uruguay


TABLE 2. Sample size for a highly complex study design for effect and design of specific proportion

Proportion	Design Effect				
	1.0	1.5	2.0	2.5	3.0
0.26-0.50	30	45	60	75	90
0.25	32	48	64	80	96
0.20	40	60	80	100	120
0.15	53	80	107	133	160
0.10	80	120	160	200	240
0.05	160	240	320	400	480

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

FIGURE 1. Sampling procedure in CESCAS I study



54x43mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This cohort study will comply with the STROBE statement for this type of observational studies

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2011-000126 on 26 May 2011. Downloaded from <http://bmjopen.bmj.com/> on December 1, 2022 by guest. Protected by copyright.